Athos KG

Munich/Holzkirchen-based single-family office of identical twin brothers Andreas and Thomas Strüngmann (both born 1950), managing ~$24-30 billion combined fortune. Founded after 2005 sale of Hexal AG (generic pharmaceuticals company founded 1986) to Novartis for €5.7 billion (including EON Labs stake). Also operates through Santo Holding (Zug, Switzerland). Most famous investment: €150M seed funding for BioNTech (2008), enabling its founding; now ~43% stake worth ~$10B - the company developed COVID-19 vaccine with Pfizer. Portfolio heavily focused on healthcare/life sciences: Formycon (biosimilars, 26.6% stake via €650M investment), Ganymed Pharmaceuticals (sold to Astellas), Schuelke & Mayr (hand sanitizer, €1.5B acquisition 2023), SHL Medical (drug delivery), Sivantos/WS Audiology (hearing aids via EQT partnerships). Also invests in: renewables (NexWafe solar wafers), real estate (Frankfurt Villa Kennedy, Munich Fünf Höfe shopping district, London office building £26M). ~40 employees. Frequent co-investments with EQT private equity. Founded Ernst-Strüngmann-Forum research institute (2007). Known for discretion, long-term commitment, sustainable entrepreneurship.